Curcumin doped zeolitic imidazolate framework nanoplatforms as multifunctional nanocarriers for tumor chemo/immunotherapy

Liu, Jingjin; Liu, Suwan; Wu, Yunchao; Xu, Xin; Li, Qianzhe; Yang, Mengyu; Gong, Aihua; Zhang, Miaomiao; Lu, Rongzhu; Du, F.

doi:10.1039/d2bm00149g

Cited by 18 publications

(14 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Except for molecular adjustment, choosing proper delivery systems is vital in applying gingerols. It can be loaded on different types of nanoparticles, such as ZIF nanoparticles, [ 130 ] zein nanoparticles, [ 131 ] and chitosan nanoparticles, [ 132 ] to enhance the delivery efficiency and realize synergistic treatment to eradicate biofilms.…”

Section: Disrupting Biofilm Integrity To Heighten the Biofilm Penetra...mentioning

confidence: 99%

Recent Nanotechnologies to Overcome the Bacterial Biofilm Matrix Barriers

Wang

Mei

et al. 2022

Small

View full text Add to dashboard Cite

Bacterial biofilms cause persistent infectious diseases and create tremendous obstacles to anti-infection treatment. [5,6] Epidemiological evidence has shown that biofilm formation poses a risk of chronic infection for clinical treatments, particularly in implant patients [7,8] such as cardiovascular grafts, fracture treatment, and orthodontic treatment. [9,10] If the biofilm infection is not cured in time, the long-term use of antibiotics to treat chronic infection may further aggravate the negative impact of antibiotics on the human body.The particular structure and components of the biofilm hinder the penetration efficiency of drugs and reduce the therapeutic effect of antibiotics, causing the hazard of bacterial biofilms. [11] In addition, some drug-resistant bacteria that inhabit the biofilms could secrete hydrolases (e.g., β-lactamases) to degrade antibiotics, making antibiotics ineffective. [12] In biofilms, the matrix, which accounts for most of the dry mass, possesses diverse functions such as the external digestive system, recycling center, gene pool, and nutrient source. [13,14] Biofilm organisms produce extracellular polymeric substances (EPS), primarily comprising exopolysaccharides, proteins, lipids, and extracellular DNA (eDNA), varying according to the environmental conditions. [15,16] EPS protects the organism from drying, oxidization, charged biocides, antibiotics, metal cations, and the host's immune defenses. [13,17,18] Additionally, EPS limits the diffusion of nutrients, creating a nutrient-deficient environment, further resulting in the slow metabolism of bacteria within the biofilm, making the bacteria less sensitive to antibiotics. [19] First, obstruction of the biofilm matrix results in extremely poor antibiotic and nutrient permeability. The aggregation of cations, such as Ca 2+ and Mg 2+ , in biofilms, promotes crosslinking between polymeric polysaccharide molecules, increasing both the viscosity and binding forces of the biofilm matrix. [20] The hydrophilic-hydrophobic properties of EPS also influence the drug penetration effect, which is related to the hydration state of EPS. [21,22] Furthermore, EPS helps immobilize bacterioplankton. The embedded bacteria in the biofilm show intense interconnections and produce stronger intercellular signal communication, a process called quorum sensing (QS). [23] Benefitting from QS, a relatively Bacterial biofilm-related infectious diseases severely influence human health. Under typical situations, pathogens can colonize inert or biological surfaces and form biofilms. Biofilms are functional aggregates that coat bacteria with extracellular polymeric substances (EPS). The main reason for the failure of biofilm infection treatment is the low permeability and enrichment of therapeutic agents within the biofilm, which results from the particular features of biofilm matrix barriers such as negatively charged biofilm components and highly viscous compact EPS structures. Hence, developing novel therapeutic strategies with enhanced biofilm penetrability is...

show abstract

Section: Disrupting Biofilm Integrity To Heighten the Biofilm Penetra...mentioning

confidence: 99%

Recent Nanotechnologies to Overcome the Bacterial Biofilm Matrix Barriers

Wang

Mei

et al. 2022

Small

View full text Add to dashboard Cite

show abstract

“…In another study, Ge et al [ 39 ] coated the surface of Cur-loaded ZIF (Cur-BMS1166@ZIF-8) with folic acid (FA)-grafted polyethylene glycol (PEG-FA) to target osteosarcoma for improved Cur delivery ( Figure 2 a). In addition, Cur-loaded ZIF can be coated with tumor cell membranes to achieve homologous tumor targeting and drug delivery [ 71 ]. Furthermore, the strategy of encapsulating Cur-loaded ZIF as guests in other host materials to form composites has been used to enhance the performance of MOFs and expand the delivery application field of Cur.…”

Section: Curcumin Nanoformulationsmentioning

confidence: 99%

Modulation of Macrophages Using Nanoformulations with Curcumin to Treat Inflammatory Diseases: A Concise Review

et al. 2022

View full text Add to dashboard Cite

Curcumin (Cur), a traditional Chinese medicine extracted from natural plant rhizomes, has become a candidate drug for the treatment of diseases due to its anti-inflammatory, anticancer, antioxidant, and antibacterial activities. However, the poor water solubility and low bioavailability of Cur limit its therapeutic effects for clinical applications. A variety of nanocarriers have been successfully developed to improve the water solubility, in vivo distribution, and pharmacokinetics of Cur, as well as to enhance the ability of Cur to polarize macrophages and relieve macrophage oxidative stress or anti-apoptosis, thus accelerating the therapeutic effects of Cur on inflammatory diseases. Herein, we review the design and development of diverse Cur nanoformulations in recent years and introduce the biomedical applications and potential therapeutic mechanisms of Cur nanoformulations in common inflammatory diseases, such as arthritis, neurodegenerative diseases, respiratory diseases, and ulcerative colitis, by regulating macrophage behaviors. Finally, the perspectives of the design and preparation of future nanocarriers aimed at efficiently exerting the biological activity of Cur are briefly discussed.

show abstract

“…A growing body of literature suggests that TP53 mutations in lung cancer are associated with increased resistance to cancer therapy and poorer survival prognosis (6), thus, mutp53 is a promising therapeutic target. Many natural or naturally derived antitumor drugs [curcumin (13), artemisinin (14), capsaicin (15)] have begun to play increasingly important roles in clinical cancer treatment (16).…”

Section: Introductionmentioning

confidence: 99%

Triptolide promotes degradation of the unfolded gain-of-function Tp53R175H/Y220C mutant protein by initiating heat shock protein 70 transcription in non-small cell lung cancer

Zhou

Luo

et al. 2022

Transl Lung Cancer Res

View full text Add to dashboard Cite

Background: The mutation rate of the tumor protein P53 (TP53) has been reported to be greater than 50% in non-small cell lung cancer (NSCLC), and gain-of-function (GOF) mutations in unfolded P53 (TP53 R175H and TP53 Y220C ) have been associated with poor prognosis. However, the best treatment for patients with NSCLC harboring unfolded mutant P53 (mutp53) remains unclear. Triptolide is a natural compound derived from Tripterygium wilfordii that has shown a strong antitumor effect in a variety of cancers. Our study aimed to explore the GOF mutations in unfolded mutp53 (TP53 R175H and TP53 Y220C ) and to clarify the molecular mechanisms by which triptolide regulates the degradation of unfolded mutp53 proteins in NSCLC.Methods: Two unfolded proteins harboring TP53 R175H and TP53 Y220C mutations were selected to explore their functions in NSCLC progression. NCI-H1299 cells (TP53-null) were transfected with wild-type TP53 (TP53 WT ), TP53 R175H , or TP53 Y220C genes and treated with triptolide or a vehicle. Wound healing and transwell assays were performed to measure cell migration and invasion in vitro. Lung metastasis models were constructed through tail vein injection of mutant cells into BALB/c nude mice to evaluate the effect of triptolide on metastasis in vivo. Western blotting, quantitative real-time polymerase chain reaction (qRT-PCR), immunoprecipitation, and dual-luciferase reporter assays were performed to explore the relevant molecular mechanisms.Results: Our study revealed that triptolide treatment reduced TP53 R175H levels and that the TP53 Y220C mutation enhanced the invasion and migration of NCI-H1299 cells. Mechanistically, triptolide promoted TP53 R175H and TP53 Y220C protein proteasomal degradation mediated through the E3 ligase murine double minute 2 (MDM2) by directly interacting with heat shock protein 70 (HSP70). Moreover, by upregulating HSP70 transcription, triptolide contributed to the protein degradation of the GOF mutp53.Conclusions: Our study reports, for the first time, the mechanism underlying triptolide-regulated protein degradation of TP53 R175H or TP53 Y220C , which offers new insight into developing a better therapeutic strategy for patients with NSCLC who express the unfolded mutp53 GOF protein. Methods Cell lines, cell culture, and reagentsHuman lung epithelial NCI-H1299 (TP53-null)

show abstract

Curcumin doped zeolitic imidazolate framework nanoplatforms as multifunctional nanocarriers for tumor chemo/immunotherapy

Abstract: Curcumin as a hydrophobic polyphenol has great potential for tumor therapy, yet rapid degradation and hydrophobicity severely impair its therapeutic effect in the clinic. Herein, we report a novel strategy...

Cited by 18 publications

References 44 publications

Recent Nanotechnologies to Overcome the Bacterial Biofilm Matrix Barriers

Recent Nanotechnologies to Overcome the Bacterial Biofilm Matrix Barriers

Modulation of Macrophages Using Nanoformulations with Curcumin to Treat Inflammatory Diseases: A Concise Review

Triptolide promotes degradation of the unfolded gain-of-function Tp53R175H/Y220C mutant protein by initiating heat shock protein 70 transcription in non-small cell lung cancer

Contact Info

Product

Resources

About